

**Class Name**

Tissue Engineering I

**Professor**

Dr. Li Cai

**Date**

Dec 11 2024

# Biocomposite Scaffolds

## For Cartilage Regeneration

Sachi Kurian, Smriti Mumudi, Jahnavi Shah,  
Emily Sullivan, Ria Suresh

# Table of Contents

01 **Background**

02 **Current Treatments**

03 **Innovation**

05 **Additional Considerations**

06 **Conclusion**



01

# Background

# Cartilage Degeneration



01

**Cartilage is an avascular,  
aneural tissue.**

02

**Common causes of cartilage damage  
include trauma, degenerative disorders,  
and congenital disorders.**

03

**Damage to cartilage results in pain,  
swelling, and reduced mobility.**


04

**Cartilage has limited  
regenerative capacity.**

Hyaline cartilage lacks blood vessels  
to facilitate repair.




# Associated Diseases



Osteoarthritis




Post-Traumatic Arthritis



Rheumatoid Arthritis




Joint Dysplasia



Chondromalacia Patellae

# Scope



**~32.5 million US Adults are affected by osteoarthritis**

**20% of patients experience chronic pain following total knee arthroplasty**

**Failure rates for cartilage repair surgeries reported up to 75%**



O2

# Current Treatments

# Current Methods (on Market and Being Studied)

01

Autologous Chondrocyte Implantation

04

Osteochondral Grafts

02

Platelet-Rich Plasma Injections

05

CartRevive™ Hydrogel Implant

03

Microfracture

06


MSC-Based Treatments

# Autologous Chondrocyte Implantation




## PROS

- Effective for large defects
- Can result in regeneration of hyaline-like cartilage
- Low rejection rates



## CONS

- Invasive and complex procedure
- Expensive
- Varied success
- Long-term post-op care required



biopsy → culturing → injection → suturing of graft → cells implanted in graft

# Platelet-Rich Plasma Injections



## PROS

- Minimal risk for immune reaction
- Reduce pain & increase function
- Less invasive than surgery




## CONS

- Inconsistency in results
- Lack of standardization in protocol
- Symptom-modifying, not structure-modifying




# Microfracture



## PROS

- Minimally invasive
- Relatively affordable



## CONS

- Results in formation of fibrocartilage
- Decline in joint functionality




# Osteochondral Grafts





## PROS

- Provides structural support
- Minimized risk of immune rejection



## CONS

- Donor site morbidity
- Limited tissue availability




# CartRevive™ Hydrogel Implant



## PROS

- Supports autologous regeneration
- Minimally invasive



## CONS


- Still under clinical investigation



# Mesenchymal Stem Cell-Based Treatments

## PROS

- MSCs have shown promise in treatment of cartilage damage and repair



## CONS

- Long-term effectiveness and safety still under investigation



03

# Innovation

Our innovation is a degradable biocomposite scaffold composed of PEGDA and collagen. The scaffold is then cultured in a medium containing synthetic cannabinoids for chondrogenesis of human mesenchymal stem cells in articular cartilage.

# Specific Aims


1



**Reduce Inflammation and Pain**

*Improve mobility and  
quality of life.*


2



**Patient Specific Temporal  
Degradation Profiles**

*Provide customized hydrogel.*

3





**Preventing Further Degradation  
and Facilitating Cartilage  
Regeneration**

*Improve joint stability.*


# Aim 1: Endocannabinoid System

## Mechanisms of Success:



# Aim 1: Endocannabinoid System

## Mechanisms of Success:




# Aim 1: Endocannabinoid System

## Mechanisms of Success:




# Aim 1: Endocannabinoid System

## Mechanisms of Success:




# Aim 2: Hydrogel Degradation




## Ester hydrolysis degradation

- Lack spatial specificity
- Biodegradation forms COOH and OH which causes
  - acidic environment which can hinder chondrogenesis.
  - accelerated degradation



VS.




## MMP-7 mediated degradation

- Cell-differentiation mediated
- Spatiotemporal control
- Mechanical stability for load bearing joints.


# Aim 3: Collagen and PEGDA Biocomposite

## Mechanisms of Success:




# Aim 3: Collagen and PEGDA Biocomposite

## Mechanisms of Success:



# Aim 3: Collagen and PEGDA Biocomposite

## Mechanisms of Success:



# Methodology of Development

**Phase I:**

**Hydrogel Preparation**

**Phase II:**

**Bioprinting and  
Crosslinking**

**Phase III:**


**Culture and  
Differentiation**

**Phase IV:**

**Assessment of Outcomes**



# Methodology

## Hydrogel Preparation




# Methodology

## Bioprinting and Crosslinking




# Methodology

## Culture and Differentiation



# Assessment of Outcomes



- **Quantify chondrogenic markers:**
  - Gene expression: qPCR for COL2A1, ACAN, and SOX9.
  - Protein expression: ELISA or immunohistochemistry
- **Histological evaluation:**
  - Proteoglycan content: Safranin O and Alcian Blue staining
  - Collagen deposition and alignment: Picosirius Red staining
- **Mechanical Properties:**
  - Young's Modulus: Compression tests
- **Cannabinoid Effect Validation:**
  - Cell proliferation: DNA quantification, BrdU assay
  - ECM deposition: GAG, collagen quantification
  - Anti-inflammatory markers: IL-10 and PGE2



# Expected Results

- **Chondrogenic markers**

- Upregulation of chondrogenic markers in MSCs
- High levels of protein levels and collagen II
  - COL2A1: >10-fold increase compared to baseline.
  - ACAN: >5-fold increase compared to baseline.
  - SOX9: >5-fold increase during early differentiation.




- **Histologic Evaluation**

- Intense staining = high proteoglycan synthesis
- Well-aligned and dense collagen fibrils

- **Mechanical Properties**




- Similar young's modulus to native: 0.1–2 MPa

- **Cannabinoid Therapeutic Effects**



# Ex Vivo Testing

- **Ex Vivo - Osteochondral Explants from Porcine Knees:**
  - Assesses integration with native cartilage and ECM deposition.




## Results

# In Vivo Testing

## Small Animal Model (Mouse)

- Biocompatibility of the scaffold and its immune response subcutaneously
- Choose multiple osteoarthritis models

## Results: Histology



**Table 1.** Mouse models of osteoarthritis.


Models	Pros	Cons
Spontaneous Wild type mice <sup>7,9,59,67,68,70,72,74,80,85,87,115,118,119,120</sup>	<ul style="list-style-type: none"> <li>- Model of aging phenotype</li> <li>- The less invasive model</li> <li>- Physiological relevance: mimics human pathogenesis</li> <li>- No need for technical expertise</li> <li>- No need for specific equipment</li> </ul>	<ul style="list-style-type: none"> <li>- Variability in incidence</li> <li>- Large number of animals at baseline</li> <li>- Long-term study: Time consuming (time of onset: 4 -15 mo)</li> <li>- Expensive (husbandry)</li> </ul>
Genetically modified mice <sup>2,7,25,40,50,52,67,72,79,80,89,120</sup>	<ul style="list-style-type: none"> <li>- High incidence</li> <li>- Earlier time of onset: 18 wk</li> <li>- No need for specific equipment</li> <li>- Combination with other models</li> </ul>	<ul style="list-style-type: none"> <li>- Time consuming for the strain development</li> <li>- Expensive</li> </ul>
Chemical-induced Mono-iodoacetate injection <sup>7,11,46,47,60,66,90,91,101,128</sup>	<ul style="list-style-type: none"> <li>- Model of pain-like phenotype</li> <li>- To study mechanism of pain and analgesic drugs</li> <li>- Short-term study: Rapid progression (2-7 wk)</li> <li>- Reproducible</li> <li>- Low cost</li> </ul>	<ul style="list-style-type: none"> <li>- Need for technical expertise</li> <li>- Need for specific equipment</li> <li>- Systemic injection is lethal</li> <li>- Destructive effect: does not allow to study the early phase of pathogenesis</li> </ul>
Papain injection <sup>66,67,120</sup>	<ul style="list-style-type: none"> <li>- Short-term study: rapid progression</li> <li>- Low cost</li> </ul>	<ul style="list-style-type: none"> <li>- Need for technical expertise</li> <li>- Need for specific equipment</li> <li>- Does not mimic natural pathogenesis</li> </ul>
Collagenase injection <sup>7,65,67,98</sup>	<ul style="list-style-type: none"> <li>- Short-term study: rapid progression (3 wk)</li> <li>- Low cost</li> </ul>	<ul style="list-style-type: none"> <li>- Need for technical expertise</li> <li>- Need for specific equipment</li> <li>- Does not mimic natural pathogenesis</li> </ul>
Non-invasive High-fat diet (Alimentary induced obesity model) <sup>5,8,43,45,57,96,124</sup>	<ul style="list-style-type: none"> <li>Model of metabolic phenotype</li> <li>No need for technical expertise</li> <li>No need for specific equipment</li> <li>Reproducible</li> </ul>	<ul style="list-style-type: none"> <li>Long-term study: Time consuming (8 wk–9 mo delay)</li> <li>Expensive</li> </ul>
Physical activity and exercise model <sup>45,73</sup>	<ul style="list-style-type: none"> <li>Model of post traumatic phenotype</li> <li>No need for technical expertise</li> </ul>	<ul style="list-style-type: none"> <li>Long-term study: time consuming (18 mo delay)</li> <li>Expensive</li> <li>Disparity of results</li> </ul>
Mechanical loading models Repetitive mild loading models Single-impact injury model <sup>7,16,23,24,32,35,104,105,106</sup>	<ul style="list-style-type: none"> <li>Model of post traumatic phenotype</li> <li>Allow to study OA development</li> <li>Time of onset: 8-10 wk post injury</li> <li>Noninvasive</li> </ul>	<ul style="list-style-type: none"> <li>Need for technical expertise</li> <li>Need for specific equipment</li> <li>Heterogeneity in protocol practices</li> <li>Repetitive anesthesia required or ethical issues</li> <li>Contested.</li> </ul>
Surgical Ovariectomy <sup>114</sup> Meniscectomy model <sup>7,32,63,67,87</sup>	<ul style="list-style-type: none"> <li>Model of post traumatic phenotype</li> <li>High incidence</li> <li>Short-term study: early time of onset (4 wk from surgery)</li> <li>To study therapies</li> </ul>	<ul style="list-style-type: none"> <li>Need for technical expertise</li> <li>Need for specific equipment</li> <li>Surgical risks</li> <li>Rapid progression compared to human</li> </ul>
Anterior cruciate ligament transection (ACLT) <sup>7,39,40,61,48,67,70,87,126</sup>	<ul style="list-style-type: none"> <li>Model of posttraumatic phenotype</li> <li>High incidence</li> <li>Short-term study: early time of onset (3-10 wk from surgery)</li> <li>Reproducible</li> <li>To study therapies</li> </ul>	<ul style="list-style-type: none"> <li>Need for technical expertise</li> <li>Need for specific equipment</li> <li>Surgical risks</li> <li>Rapid progression compared to human</li> </ul>
Destabilization of medial meniscus (DMM) <sup>7,32,39,40</sup>	<ul style="list-style-type: none"> <li>Model of post traumatic phenotype</li> <li>High incidence</li> <li>Short-term study: early time of onset (4 wk from surgery)</li> <li>To study therapies</li> <li>The most frequently used method</li> </ul>	<ul style="list-style-type: none"> <li>Need for technical expertise</li> <li>Need for specific equipment</li> <li>Surgical risks</li> <li>Rapid progression compared to human</li> </ul>

Since all animal models have strengths and weaknesses, it is often best to plan using a number of models and techniques together to combine the results.


# In Vivo Testing

## Large Animal Model (Sheep)

- Create osteochondral defects (5–10 mm diameter) in the femoral condyles of sheep knees
- Surgically implant scaffold
- Restrict joint movement for 1–2 weeks, followed by gradual reintroduction of load-bearing activities.
- If possible obtain samples at different time points or have multiple animals euthanized at different time points.



## Results



# Limitations and Challenges

## 1. Immune Rejection, Inflammation, Side Effects



- a. Carcinogenicity, cytotoxicity, excessive inflammatory response

## 2. Scalability and Cost

- b. Small scale we will be using 3D bioprinters to print scaffolds for crosslinking, how will we increase the scale?
- c. How will we ensure sterility?

## 3. Long-Term Integration and Mechanical Strength

- d. Is the regenerated cartilage mechanically stable?
- e. Is the integration mechanism replicable?



# Addressing Limitations

## 1. Immune Rejection, Inflammation, Side Effects


- a. Biocompatible coatings/hydrogels
- b. Dose-controlled release of cannabinoids
- c. Extensive preclinical safety testing

## 2. Scalability and Cost

- a. Automated bioprinting systems
- b. Closed-loop sterile manufacturing processes
- c. Partner with manufacturers

## 3. Long-Term Integration and Mechanical Strength

- a. Gradient mechanical properties to match tissue
- b. Enhance cross linking techniques for durability
- c. Perform in vivo validation to ensure long-term functionality





04

# Additional Considerations

# Additional Considerations:

## Synthetic vs. Natural Cannabinoids

**WIN5, 212-2**

No psychoactive effects



Suitable for in vitro/vivo studies

Limited long term safety data challenging clinical adoption



**Delta9-THC**

Widely studied, naturally occurring



Established medical frameworks for use

Psychoactive and risk of tolerance and dependency

# Additional Considerations:



## Varying THC and CBD Combinations

### THC

- Pain management
- Immune modulation

### CBD

- Anti-inflammatory
- Cartilage protective
- Promotes chondrogenesis
- Reduces pain






05

# Conclusion

# Conclusion

- **Our Solution:**
  - Designed a biocomposite scaffold combining PEGDA and collagen cultured in a medium containing synthetic cannabinoids for patient-specific cartilage regeneration
- **Our Intended Outcomes:**
  - Enhanced tissue integration, structural stability, and quality of life for patients
- **Possible Next Steps:**
  - Address scalability, long-term safety, and clinical testing for real-world applications
- **Our Key Takeaway:**
  - This innovative scaffold merges advanced materials and biological insights to address critical challenges in cartilage repair



# Thank You

Any Questions?

# References

- Arthritis Foundation. (n.d.). Osteoarthritis. Arthritis Foundation. Retrieved December 13, 2024, from <https://www.arthritis.org/diseases/osteoarthritis>
- Arthritis Foundation. (n.d.). The future of joint repair. Arthritis Foundation. Retrieved December 13, 2024, from <https://www.arthritis.org/health-wellness/treatment/joint-surgery/preplanning/the-future-of-joint-repair>
- Atalay, S., Jarocka-Karpowicz, I., & Skrzylewska, E. (2020). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants*, 9(1), 21. <https://doi.org/10.3390/antiox9010021>
- Bahney, C. S., Hsu, C. W., Yoo, J. U., West, J. L., & Johnstone, B. (2011). A bioresponsive hydrogel tuned to chondrogenesis of human mesenchymal stem cells. *FASEB Journal*, 25(5), 1486–1496. <https://doi.org/10.1096/fj.10-165514>
- Chen-Chan Hsieh, B. Linju Yen, Chia-Chi Chang, Pei-Ju Hsu, Yu-Wei Lee, Men-Luh Yen, Shaw-Fang Yet, Linyi Chen, Wnt antagonism without TGF $\beta$  induces rapid MSC chondrogenesis via increasing AJ interactions and restricting lineage commitment, *iScience*, Volume 26, Issue 1, 2023, 105713, ISSN 2589-0042, <https://doi.org/10.1016/j.isci.2022.105713>.(<https://www.sciencedirect.com/science/article/pii/S2589004222019861>).
- Cong, B., Sun, T., Zhao, Y., & Chen, M. (2023). Current and Novel Therapeutics for Articular Cartilage Repair and Regeneration. *Therapeutics and Clinical Risk Management*, 19, 485–502. <https://doi.org/10.2147/TCRM.S410277>
- Gowran A, McKayed K, Kanichai M, White C, Hammadi N, Campbell V. *Tissue Engineering of Cartilage; Can Cannabinoids Help?* *Pharmaceuticals (Basel)*. 2010 Sep 6;3(9):2970-2985. doi: 10.3390/ph3092970. PMID: 27713386; PMCID: PMC4034107.
- Hy2Care. (n.d.). Home. Hy2Care. Retrieved December 13, 2024, from <https://www.hy2care.com/en>
- Hu B, Gao J, Lu Y, Wang Y. Applications of Degradable Hydrogels in Novel Approaches to Disease Treatment and New Modes of Drug Delivery. *Pharmaceutics*. 2023; 15(10):2370. <https://doi.org/10.3390/pharmaceutics15102370>
- Kalapa Clinic. (n.d.). Cannabinoids for cartilage tissue repair. Kalapa Clinic. Retrieved December 13, 2024, from <https://www.kalapa-clinic.com/en/cannabinoids-cartilage-tissue-repairing/>
- Lee, M., & Kwon, Y. (2014). The effect of a synthetic cannabinoid on cartilage repair. *European Journal of Pharmacology*, 730, 51-58. <https://doi.org/10.1016/j.ejphar.2014.03.014>
- Liao, M., & Zhang, X. (2016). Chondrogenic gene expression profile by in vitro matured constructs: RT-qPCR analysis. *ResearchGate*. <https://doi.org/10.13140/RG.2.2.15609.12640>
- Mazzantini C, El Bourji Z, Parisio C, Davolio PL, Cocchi A, Pellegrini-Giampietro DE, Landucci E. Anti-Inflammatory Properties of Cannabidiol and Beta-Caryophyllene Alone or Combined in an In Vitro Inflammation Model. *Pharmaceutics*. 2024; 17(4):467. <https://doi.org/10.3390/ph17040467>
- Moreno-Castellanos, N., Cuartas-Gómez, E., & Vargas-Ceballos, O. (2023). Functionalized Collagen/Poly(ethylene glycol) Diacrylate Interpenetrating Network Hydrogel Enhances Beta Pancreatic Cell Sustenance. *Gels*, 9(6), 496. <https://doi.org/10.3390/gels9060496>
- Redondo, M. L., Beer, A. J., & Yanke, A. B. (2018). Cartilage restoration: Microfracture and osteochondral autograft transplantation. *The Journal of Knee Surgery*, 31(03), 231–238. <https://doi.org/10.1055/s-0037-1618592>
- Roseti, L., Grigolo, B. Current concepts and perspectives for articular cartilage regeneration. *J EXP ORTOP* 9, 61 (2022). <https://doi.org/10.1186/s40634-022-00498-4>
- Ruhl T, Karthaus N, Kim BS, Beier JP. The endocannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub> affect the regenerative potential of adipose tissue MSCs. *Exp Cell Res.* 2020 Apr 1;389(1):111881. doi: 10.1016/j.yexcr.2020.111881. Epub 2020 Jan 29. PMID: 32006556.
- Schlüter, J. M., & Luedke, M. (2017). Chondrogenic gene expression profile by in vitro matured constructs. *Thieme Connect*. <https://doi.org/10.1055/s-0037-1618592>
- Sharma, S., & Gupta, A. (2017). Inflammation in the context of endocarditis of a Contegra® graft (EvG staining). *ResearchGate*. <https://doi.org/10.13140/RG.2.2.14289.62560>
- SteinerBio. (n.d.). How the immune system determines bone graft success or failure. SteinerBio. Retrieved December 13, 2024, from <https://www.steinerbio.com/how-the-immune-system-determines-bone-graft-success-or-failure/>